A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy

Trial Profile

A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Olaparib (Primary) ; Paclitaxel
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GOLD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Nov 2017 Results published in the Lancet Oncology
    • 30 Nov 2016 Planned End Date changed from 1 Feb 2018 to 1 Jan 2018.
    • 11 Oct 2016 Results (n=521) of a final analysis evaluating safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top